Today: 24 March 2026
Subscribe
Browse Category

NASDAQ:IBIO 21 October 2025 - 13 March 2026

ImmunityBio Stock Jumps After NK-Cell Manufacturing Update Puts Anktiva Expansion Back in Focus

ImmunityBio Stock Jumps After NK-Cell Manufacturing Update Puts Anktiva Expansion Back in Focus

ImmunityBio shares jumped 10.5% to $8.64 by early afternoon Friday after the company announced completion of a scalable manufacturing process for its NK-cell therapy platform. The update follows FDA acknowledgment of a resubmitted application for expanded use of Anktiva in papillary bladder cancer and recent approval of the drug in 33 countries. Investors remain cautious due to ongoing regulatory and financial risks.
13 March 2026
·
iBio (IBIO) Stock Jumps on Obesity Drug Momentum: All the Latest News, Analyst Targets and 2026–2027 Outlook (December 9, 2025)

iBio (IBIO) Stock Jumps on Obesity Drug Momentum: All the Latest News, Analyst Targets and 2026–2027 Outlook (December 9, 2025)

iBio, Inc. shares surged 39% Monday to close at $1.67 on heavy volume, lifting its market value to about $37.5 million. The stock traded higher pre-market Tuesday, with quotes between $1.76 and $1.81. The company reported $49.6 million in cash after a recent offering and says this will fund operations into late 2027. Lead obesity drug candidate IBIO-610 has shown fat-selective weight loss in animal studies.
9 December 2025
·
iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

iBio (NASDAQ: IBIO) traded at $0.89 midday October 21, down 63% year-to-date from $2.45 in January. Shares jumped over 20% last week after bullish “Outperform” ratings from Oppenheimer and Leerink Partners, with price targets of $5.00 and $2.00. The company reported positive preclinical results for its obesity drug IBIO-610 and raised $50 million in a recent offering. Market cap stands near $18 million.
21 October 2025
·

Stock Market Today

  • Micron stock falls 15% despite strong Q2 earnings and AI-driven demand
    March 24, 2026, 3:52 PM EDT. Micron's stock has fallen about 15% in four days despite a dominant second-quarter earnings report that showed revenue tripling to $23.86 billion. The memory chip maker benefits from soaring demand for artificial intelligence (AI) chips, which require large memory supplies. CEO Sanjay Mehrotra said supply is tight, delivering only 50% to two-thirds of key customers' needs. Micron's strong guidance includes gross margins around 80%. Analysts from Bank of America, Morgan Stanley, and JPMorgan raised price targets after the report. Despite the recent dip, Micron is up over 300% in the past year, uniquely gaining among top U.S. tech firms, while others like Microsoft and Oracle declined more than 20%. The stock fall may reflect profit-taking amid concerns over rising capital expenditure and peak gross margins.
Go toTop